ATE504302T1 - Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten - Google Patents

Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten

Info

Publication number: ATE504302T1
Authority: AT; Austria
Prior art keywords: methods; reducing; preventing pain; spicamycin derivatives; spicamycin
Prior art date: 2000-09-20

Application number

AT01971222T

Other languages

English (en)

Inventor

David Borsook

Original Assignee

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-20

Filing date

2001-09-20

Publication date

2011-04-15

2001-09-20 Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE504302T1 publication Critical patent/ATE504302T1/de

Links

YBZRLMLGUBIIDN-NZSGCTDASA-N spicamycin Chemical class O1[C@@H](C(O)CO)[C@H](NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)[C@@H](O)[C@@H](O)[C@H]1NC1=NC=NC2=C1N=CN2 YBZRLMLGUBIIDN-NZSGCTDASA-N 0.000 title abstract 2
YBZRLMLGUBIIDN-UHFFFAOYSA-N spicamycin Natural products O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01971222T 2000-09-20 2001-09-20 Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten ATE504302T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23438200P	2000-09-20	2000-09-20
PCT/US2001/029371 WO2002024146A2 (en)	2000-09-20	2001-09-20	Methods of decreasing or preventing pain using spicamycin derivatives

Publications (1)

Publication Number	Publication Date
ATE504302T1 true ATE504302T1 (de)	2011-04-15

Family

ID=22881151

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01971222T ATE504302T1 (de)	2000-09-20	2001-09-20	Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten

Country Status (9)

Country	Link
US (3)	US7196071B2 (de)
EP (2)	EP1328236B1 (de)
JP (1)	JP5016777B2 (de)
AT (1)	ATE504302T1 (de)
AU (1)	AU2001291133A1 (de)
CA (1)	CA2425172C (de)
DE (1)	DE60144383D1 (de)
ES (1)	ES2365473T3 (de)
WO (1)	WO2002024146A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002024146A2 (en) *	2000-09-20	2002-03-28	The General Hospital Corporation	Methods of decreasing or preventing pain using spicamycin derivatives
CN1668735A (zh) *	2002-05-22	2005-09-14	国立大学法人香川大学	稀有糖的生物活性的利用方法及配合了稀有糖的组合物
US7860552B2 (en) *	2004-10-01	2010-12-28	The Mclean Hospital Corporation	CNS assay for prediction of therapeutic efficacy for neuropathic pain and other functional illnesses
JP5116071B2 (ja)	2005-07-20	2013-01-09	帝國製薬株式会社	Ｄ−アロースおよびｄ−プシコースの抗神経因性疼痛効果の利用
ES2567455T3 (es)	2008-10-10	2016-04-22	Dara Biosciences, Inc.	Nanoemulsiones que comprenden derivados de espicamicina para su uso en el tratamiento del dolor
AU2013299560A1 (en)	2012-08-09	2015-02-26	Dara Biosciences, Inc.	Compositions comprising spicamycin derivatives and methods of use thereof
US10262107B1 (en) *	2013-03-15	2019-04-16	Bao Tran	Pharmacogenetic drug interaction management system
WO2015061481A1 (en)	2013-10-23	2015-04-30	Dara Biosciences, Inc.	Methods of treating liquid tumors using compositions comprising spicamycin derivatives
US10732507B2 (en)	2015-10-26	2020-08-04	Esko-Graphics Imaging Gmbh	Process and apparatus for controlled exposure of flexographic printing plates and adjusting the floor thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5252463A (en) *	1990-06-22	1993-10-12	The Du Pont Merck Pharmaceutical Company	Clipsin, a chymotrypsin-like protease and method of using same
JP2783722B2 (ja)	1991-07-12	1998-08-06	麒麟麦酒株式会社	スピカマイシン誘導体およびそれを含む抗腫瘍剤
US5824645A (en) *	1991-12-30	1998-10-20	Neurex Corporation	Method of treating inflammation
US6013853A (en)	1992-02-14	2000-01-11	The University Of Texas System	Continuous release polymeric implant carrier
US5905069A (en) *	1998-01-26	1999-05-18	The General Hospital Corporation	Methods of decreasing or preventing pain using spicamycin or derivatives thereof
WO2002024146A2 (en) *	2000-09-20	2002-03-28	The General Hospital Corporation	Methods of decreasing or preventing pain using spicamycin derivatives

2001
- 2001-09-20 WO PCT/US2001/029371 patent/WO2002024146A2/en not_active Ceased
- 2001-09-20 US US10/380,354 patent/US7196071B2/en not_active Expired - Fee Related
- 2001-09-20 EP EP01971222A patent/EP1328236B1/de not_active Expired - Lifetime
- 2001-09-20 EP EP10185635A patent/EP2305264A1/de not_active Withdrawn
- 2001-09-20 AU AU2001291133A patent/AU2001291133A1/en not_active Abandoned
- 2001-09-20 CA CA2425172A patent/CA2425172C/en not_active Expired - Fee Related
- 2001-09-20 DE DE60144383T patent/DE60144383D1/de not_active Expired - Lifetime
- 2001-09-20 AT AT01971222T patent/ATE504302T1/de not_active IP Right Cessation
- 2001-09-20 ES ES01971222T patent/ES2365473T3/es not_active Expired - Lifetime
- 2001-09-20 JP JP2002528183A patent/JP5016777B2/ja not_active Expired - Fee Related
2007
- 2007-03-15 US US11/686,510 patent/US7375094B2/en not_active Expired - Fee Related
2008
- 2008-04-30 US US12/112,213 patent/US7632825B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2002024146A9 (en)	2004-05-13
EP1328236A4 (de)	2005-10-26
US20070161597A1 (en)	2007-07-12
EP1328236A2 (de)	2003-07-23
WO2002024146A2 (en)	2002-03-28
US20080207557A1 (en)	2008-08-28
EP1328236B1 (de)	2011-04-06
AU2001291133A1 (en)	2002-04-02
CA2425172A1 (en)	2002-03-28
EP2305264A1 (de)	2011-04-06
US7632825B2 (en)	2009-12-15
JP5016777B2 (ja)	2012-09-05
JP2004537494A (ja)	2004-12-16
US7196071B2 (en)	2007-03-27
WO2002024146A3 (en)	2003-05-22
US20040038927A1 (en)	2004-02-26
US7375094B2 (en)	2008-05-20
DE60144383D1 (de)	2011-05-19
ES2365473T3 (es)	2011-10-06
CA2425172C (en)	2011-02-01

Similar Documents

Publication	Publication Date	Title
NO2022001I1 (no)	2022-01-06	Pazopanib
DE602004027936D1 (de)	2010-08-12	Tocopherolmodifizierte therapeutische arzneimittelverbindung
BRPI0411743A (pt)	2006-08-08	método e composições para tratar doenças relacionadas a amilóides
PT1214936E (pt)	2004-12-31	Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
ATE344029T1 (de)	2006-11-15	Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern
TR200002965T2 (tr)	2001-05-21	Enfeksiyonların terapötik ve profilaktik tedavisi için organofosforlu terkiplerin kullanımı
TW200600087A (en)	2006-01-01	Methods and compositions for treating amyloid-related diseases
HN1997000012A (es)	1997-06-26	Derivados de triazol utiles en terapia.
DE69814394D1 (de)	2003-06-12	Verwendung von levobupivacain
DE60118544D1 (de)	2006-05-18	Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
DE60108581D1 (de)	2005-03-03	Implantierbarer Herzschrittmacher
AR032293A1 (es)	2003-11-05	Estuche farmaceutico
BR0114059A (pt)	2003-07-01	Derivados de resorcinol
DE60108857D1 (de)	2005-03-17	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE504302T1 (de)	2011-04-15	Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
DE69830577D1 (de)	2005-07-21	Halo-alkoxycarbonylverbindungen
ATE332688T1 (de)	2006-08-15	Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
EE200300129A (et)	2003-06-16	Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
TR200302134T4 (tr)	2004-01-21	2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
DE50111407D1 (de)	2006-12-21	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
NO20005548D0 (no)	2000-11-03	Mykobakterieinhibitorer
CY1105317T1 (el)	2010-03-03	Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el)	2009-11-04	Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CO5021190A1 (es)	2001-03-27	Agentes terapeuticos
DE69807200D1 (de)	2002-09-19	Inklusionskomplexe in waessriger loesung

Legal Events

Date	Code	Title	Description
2011-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties